Nabriva Therapeutics PLC (NBRVF)
OTC PINK OTC PINK Primary Summary
Nabriva Therapeutics PLC (NBRVF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nabriva Therapeutics PLC ever had a stock split?
Nabriva Therapeutics PLC Profile
| Biotechnology Industry | Healthcare Sector | H. Michael Hogan CEO | OTC PINK Exchange | IE000OZRGNV6 ISIN |
| IE Country | 39 Employees | - Last Dividend | 16 Sep 2022 Last Split | - IPO Date |
Overview
Nabriva Therapeutics plc is a biopharmaceutical company that has dedicated its resources to the development and commercialization of novel anti-infective agents for treating serious infections. The company was originally established as Nabriva Therapeutics Forschungs GmbH before undergoing a name change to Nabriva Therapeutics plc in 2007. Since its incorporation in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics has been at the forefront of creating innovative solutions to combat challenging infections, leveraging its expertise in anti-infective research and development.
Products and Services
- SIVEXTRO (oxazolidinone-class antibacterial)
This antibacterial is designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Its classification as an oxazolidinone-class antibacterial signifies its use in tackling severe skin infections, providing a strategic option in the antimicrobial arsenal against resistant bacteria.
- XENLETA (semi-synthetic pleuromutilin antibiotic)
XENLETA, available for both oral and IV administration, represents a significant advancement in the treatment of infections. Primarily used in adults, this semi-synthetic pleuromutilin antibiotic is indicated for community-acquired bacterial pneumonia (CABP). Furthermore, XENLETA is undergoing Phase I clinical trials for several other potential applications, including pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. These ongoing trials underscore the versatile potential of XENLETA in treating a wide array of bacterial infections.
- CONTEPO (epoxide antibiotic)
CONTEPO stands out as an innovative epoxide antibiotic designed primarily to treat complicated urinary tract infections (cUTI). Beyond its primary indication, CONTEPO is also being evaluated in Phase I clinical trials for peri-operative prophylaxis. This highlights the company’s commitment to broadening the applications of its antibacterial agents to meet a wide range of clinical needs.
